Parkinson David Ross's Form 4 filing
ESSA Pharma Inc. (EPIX) · filed Jan 5, 2023
- Accession no.
- 0000899243-23-001039
- Filed
- Jan 5, 2023
- Trade date
- Dec 22-30, 2022
- Filing delay
- 14 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions. Open-market purchases total $59.0K. It was filed 14 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Parkinson David RossCIK 0001451935 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 22, 2022 | Common Shares | PPurchaseAcquired | +21,367 | $2.39 | +$51,067.13 | 53,475 | Direct | |
| Dec 30, 2022 | Common Shares | PPurchaseAcquired | +3,067 | $2.60 | +$7,974.2 | 56,542 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.